Cytokinetics at Stifel 2026 Healthcare Conference: aficamten gains

On Tuesday, November 10, 2026, Cytokinetics (CYTK) presented its growth trajectory at the Stifel 2026 Healthcare Conference. The company highlighted that aficamten, its hypertrophic cardiomyopathy (HCM) treatment, is rapidly gaining market share. Aficamten reached 45% new-to-brand share within eight months of launch, with revenue surging 76% from the previous quarter.

Patient dispensations increased to more than 2,800 from 1,500, reflecting faster adoption in the HCM market. The drug's flexible dosing, shorter half-life, and simpler REMS (Risk Evaluation and Mitigation Strategy) are contributing to its uptake, particularly among community cardiologists.

Cytokinetics anticipates filing for non-obstructive HCM next week, seeing this as a significant market expansion opportunity. The company concluded the quarter with $1.6 billion in cash and investments, with potential cash flow positivity within 2 to 2.5 years. Aficamten's commercial launch appears to be gaining momentum, with revenue rising 76% quarter over quarter and patient dispensations up to more than 2,800.

The broader cardiomyopathy market grew 45% year over year, indicating the class itself is expanding. New-to-brand share reached 45% within eight months, with about 80% of prescriptions in the 5-10 milligram maintenance range. Physicians are using the full two- to eight-week titration window, with an average use of four to six weeks. More than 3,000 healthcare professionals have been certified under the REMS program, with two-thirds actively writing prescriptions or affiliated with prescribers.

Management emphasized that the drug's clinical profile and prescribers' confidence are driving the launch. The dosing and monitoring window is more flexible than competing products, and the REMS is less burdensome. Community cardiologists, lacking specialized infrastructure, are more willing to prescribe aficamten. Switching from its competitor CAMZYOS is not a major strategic focus; instead, the company is targeting broader prescriber adoption.

Access has not been a major bottleneck, although some payer blocks remain. Medicare coverage stands at 90% of lives at parity with CAMZYOS, while commercial coverage has increased to 60%.

The next major catalyst for Cytokinetics is a filing for non-obstructive HCM indication, expected next week. The company expects this to build on the MAPLE-HCM program and ACACIA-HCM data set. The sNDA for MAPLE-HCM is anticipated next week, with European launches planned for early 2027.